Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Beijing Tongrentang

SHSE:600085
Snowflake Description

Flawless balance sheet established dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
600085
SHSE
CN¥34B
Market Cap
  1. Home
  2. CN
  3. Pharmaceuticals & Biotech
Company description

Beijing Tongrentang Co., Ltd engages in the scientific research, production, sale, and distribution of Chinese medicines in China and internationally. The last earnings update was 154 days ago. More info.


Add to Portfolio Compare Print
600085 Share Price and Events
7 Day Returns
0.2%
SHSE:600085
4.7%
CN Pharmaceuticals
0.5%
CN Market
1 Year Returns
-19.5%
SHSE:600085
3.3%
CN Pharmaceuticals
-8.7%
CN Market
600085 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Beijing Tongrentang (600085) 0.2% -6.5% -11.5% -19.5% -21.5% -14.9%
CN Pharmaceuticals 4.7% 2.2% 5.4% 3.3% 1% -2.5%
CN Market 0.5% -6.3% -5.7% -8.7% -15.2% -25.9%
1 Year Return vs Industry and Market
  • 600085 underperformed the Pharmaceuticals industry which returned 3.3% over the past year.
  • 600085 underperformed the Market in China which returned -8.7% over the past year.
Price Volatility
600085
Industry
5yr Volatility vs Market

600085 Value

 Is Beijing Tongrentang undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Beijing Tongrentang to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Beijing Tongrentang.

SHSE:600085 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year CN Government Bond Rate 3.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SHSE:600085
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CN Govt Bond Rate 3.2%
Equity Risk Premium S&P Global 6.3%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.692 (1 + (1- 25%) (4.49%))
0.809
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.2% + (0.809 * 6.33%)
8.32%

Discounted Cash Flow Calculation for SHSE:600085 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Beijing Tongrentang is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SHSE:600085 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8.32%)
2020 1,070.00 Analyst x1 987.79
2021 1,221.00 Analyst x1 1,040.58
2022 1,281.00 Analyst x1 1,007.83
2023 1,593.00 Analyst x1 1,157.00
2024 1,526.00 Analyst x1 1,023.18
2025 1,498.52 Est @ -1.8% 927.55
2026 1,494.01 Est @ -0.3% 853.71
2027 1,505.21 Est @ 0.75% 794.02
2028 1,527.56 Est @ 1.48% 743.90
2029 1,558.10 Est @ 2% 700.47
Present value of next 10 years cash flows CN¥9,236.00
SHSE:600085 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥1,558.10 × (1 + 3.2%) ÷ (8.32% – 3.2%)
CN¥31,387.31
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥31,387.31 ÷ (1 + 8.32%)10
CN¥14,110.71
SHSE:600085 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥9,236.00 + CN¥14,110.71
CN¥23,346.71
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥23,346.71 / 1,371.47
CN¥17.02
SHSE:600085 Discount to Share Price
Calculation Result
Value per share (CNY) From above. CN¥17.02
Current discount Discount to share price of CN¥24.85
= -1 x (CN¥24.85 - CN¥17.02) / CN¥17.02
-46%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Beijing Tongrentang is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Beijing Tongrentang's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Beijing Tongrentang's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SHSE:600085 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CNY CN¥0.83
SHSE:600085 Share Price ** SHSE (2020-04-01) in CNY CN¥24.85
China Pharmaceuticals Industry PE Ratio Median Figure of 157 Publicly-Listed Pharmaceuticals Companies 31.4x
China Market PE Ratio Median Figure of 3,194 Publicly-Listed Companies 31.97x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Beijing Tongrentang.

SHSE:600085 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SHSE:600085 Share Price ÷ EPS (both in CNY)

= 24.85 ÷ 0.83

30.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Beijing Tongrentang is good value based on earnings compared to the CN Pharmaceuticals industry average.
  • Beijing Tongrentang is good value based on earnings compared to the China market.
Price based on expected Growth
Does Beijing Tongrentang's expected growth come at a high price?
Raw Data
SHSE:600085 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 30.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
11.1%per year
China Pharmaceuticals Industry PEG Ratio Median Figure of 55 Publicly-Listed Pharmaceuticals Companies 1.58x
China Market PEG Ratio Median Figure of 1,275 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

SHSE:600085 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 30.05x ÷ 11.1%

2.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Beijing Tongrentang is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Beijing Tongrentang's assets?
Raw Data
SHSE:600085 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CNY CN¥7.14
SHSE:600085 Share Price * SHSE (2020-04-01) in CNY CN¥24.85
China Pharmaceuticals Industry PB Ratio Median Figure of 174 Publicly-Listed Pharmaceuticals Companies 2.63x
China Market PB Ratio Median Figure of 3,689 Publicly-Listed Companies 2.23x
SHSE:600085 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SHSE:600085 Share Price ÷ Book Value per Share (both in CNY)

= 24.85 ÷ 7.14

3.48x

* Primary Listing of Beijing Tongrentang.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Beijing Tongrentang is overvalued based on assets compared to the CN Pharmaceuticals industry average.
X
Value checks
We assess Beijing Tongrentang's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Beijing Tongrentang has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

600085 Future Performance

 How is Beijing Tongrentang expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Beijing Tongrentang expected to grow at an attractive rate?
  • Beijing Tongrentang's earnings growth is expected to exceed the low risk savings rate of 3.2%.
Growth vs Market Checks
  • Beijing Tongrentang's earnings growth is positive but not above the China market average.
  • Beijing Tongrentang's revenue growth is positive but not above the China market average.
Annual Growth Rates Comparison
Raw Data
SHSE:600085 Future Growth Rates Data Sources
Data Point Source Value (per year)
SHSE:600085 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 11.1%
SHSE:600085 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 8.1%
China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 23.2%
China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 18.4%
China Market Earnings Growth Rate Market Cap Weighted Average 21%
China Market Revenue Growth Rate Market Cap Weighted Average 15.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SHSE:600085 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SHSE:600085 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 17,776 2,240 1,607 1
2021-12-31 16,975 1,944 1,396 5
2020-12-31 15,925 1,697 1,273 6
2020-04-01
2019-12-31 14,262 1,658 1,109 3
SHSE:600085 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-09-30 13,691 2,285 1,135
2019-06-30 14,098 2,007 1,156
2019-03-31 14,455 1,896 1,167
2018-12-31 14,209 1,928 1,134
2018-09-30 14,070 1,907 1,048
2018-06-30 13,644 1,598 1,057
2018-03-31 13,373 1,642 1,040
2017-12-31 13,376 1,473 1,017
2017-09-30 12,978 1,234 994
2017-06-30 12,705 1,245 970
2017-03-31 12,480 1,034 965
2016-12-31 12,091 1,046 933

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Beijing Tongrentang's earnings are expected to grow by 11.1% yearly, however this is not considered high growth (20% yearly).
  • Beijing Tongrentang's revenue is expected to grow by 8.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SHSE:600085 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Beijing Tongrentang Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:600085 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 1.17 1.17 1.17 1.00
2021-12-31 1.02 1.12 0.95 7.00
2020-12-31 0.93 1.00 0.87 7.00
2020-04-01
2019-12-31 0.83 0.85 0.80 5.00
SHSE:600085 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-09-30 0.83
2019-06-30 0.84
2019-03-31 0.85
2018-12-31 0.83
2018-09-30 0.76
2018-06-30 0.77
2018-03-31 0.76
2017-12-31 0.74
2017-09-30 0.72
2017-06-30 0.71
2017-03-31 0.70
2016-12-31 0.68

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Beijing Tongrentang is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Beijing Tongrentang's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Beijing Tongrentang has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

600085 Past Performance

  How has Beijing Tongrentang performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Beijing Tongrentang's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Beijing Tongrentang's year on year earnings growth rate has been positive over the past 5 years.
  • Beijing Tongrentang's 1-year earnings growth is less than its 5-year average (8.3% vs 8.5%)
  • Beijing Tongrentang's earnings growth has not exceeded the CN Pharmaceuticals industry average in the past year (8.3% vs 9.8%).
Earnings and Revenue History
Beijing Tongrentang's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Beijing Tongrentang Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:600085 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 13,690.55 1,134.65 4,103.47 103.60
2019-06-30 14,098.39 1,155.60 4,101.37 105.94
2019-03-31 14,455.27 1,166.53 4,243.39 102.28
2018-12-31 14,208.64 1,134.28 4,178.59 90.65
2018-09-30 14,069.51 1,047.82 4,042.75 107.36
2018-06-30 13,643.68 1,056.95 3,862.41 120.08
2018-03-31 13,372.75 1,040.34 3,740.60 98.64
2017-12-31 13,375.97 1,017.38 3,721.86 90.94
2017-09-30 12,977.72 994.37 3,678.42 33.62
2017-06-30 12,705.26 969.71 3,644.37
2017-03-31 12,480.01 964.68 3,527.00
2016-12-31 12,090.74 933.17 3,455.49
2016-09-30 11,787.95 970.23 3,366.02
2016-06-30 11,588.43 948.64 3,265.14
2016-03-31 11,106.26 898.09 3,115.02
2015-12-31 10,896.52 875.44 3,067.55
2015-09-30 10,448.79 847.54 2,901.78
2015-06-30 10,190.38 827.74 2,824.00
2015-03-31 9,815.62 792.60 2,618.22
2014-12-31 9,685.87 763.67 2,540.93
2014-09-30 9,281.40 728.01 2,366.68
2014-06-30 9,134.20 709.47 2,373.12
2014-03-31 8,874.28 677.20 2,324.39
2013-12-31 8,714.65 656.01 2,303.73
2013-09-30 8,355.55 639.78 2,201.25
2013-06-30 8,375.14 635.33 2,190.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Beijing Tongrentang has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Beijing Tongrentang used its assets less efficiently than the CN Pharmaceuticals industry average last year based on Return on Assets.
  • Beijing Tongrentang's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Beijing Tongrentang's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Beijing Tongrentang has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

600085 Health

 How is Beijing Tongrentang's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Beijing Tongrentang's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Beijing Tongrentang is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Beijing Tongrentang's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Beijing Tongrentang's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 10.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Beijing Tongrentang Company Filings, last reported 6 months ago.

SHSE:600085 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 15,392.19 1,531.67 8,162.05
2019-06-30 15,019.54 1,423.25 7,502.94
2019-03-31 15,072.75 1,293.32 7,216.65
2018-12-31 14,529.29 1,502.36 6,857.88
2018-09-30 14,160.98 1,297.46 6,463.71
2018-06-30 13,662.23 1,532.75 6,445.19
2018-03-31 13,621.74 1,262.24 6,122.08
2017-12-31 13,168.11 1,540.82 5,906.98
2017-09-30 12,830.75 1,311.99 5,770.45
2017-06-30 12,499.79 1,551.13 6,269.75
2017-03-31 12,569.54 1,301.73 5,735.49
2016-12-31 12,078.33 1,473.35 5,859.22
2016-09-30 11,729.83 1,293.29 5,663.50
2016-06-30 11,362.03 524.08 5,200.61
2016-03-31 11,318.49 362.84 4,959.30
2015-12-31 10,881.39 523.69 4,763.20
2015-09-30 10,451.55 259.68 4,677.72
2015-06-30 10,049.32 409.34 5,124.81
2015-03-31 10,094.14 232.61 4,858.85
2014-12-31 8,646.46 1,287.54 4,617.51
2014-09-30 8,360.98 1,200.34 4,651.03
2014-06-30 8,128.72 1,331.82 5,131.37
2014-03-31 8,197.65 1,214.98 5,113.69
2013-12-31 7,837.40 1,348.17 4,938.26
2013-09-30 7,620.72 1,274.95 5,191.48
2013-06-30 6,321.69 1,572.99 4,583.01
  • Beijing Tongrentang's level of debt (10%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (14.4% vs 10% today).
  • Debt is well covered by operating cash flow (149.2%, greater than 20% of total debt).
  • Beijing Tongrentang earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Beijing Tongrentang's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Beijing Tongrentang has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

600085 Dividends

 What is Beijing Tongrentang's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.05%
Current annual income from Beijing Tongrentang dividends. Estimated to be 1.5% next year.
If you bought CN¥2,000 of Beijing Tongrentang shares you are expected to receive CN¥21 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Beijing Tongrentang's pays a higher dividend yield than the bottom 25% of dividend payers in China (0.46%).
  • Beijing Tongrentang's dividend is below the markets top 25% of dividend payers in China (2.04%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SHSE:600085 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 137 Stocks 1.3%
China Market Average Dividend Yield Market Cap Weighted Average of 2582 Stocks 1.9%
China Minimum Threshold Dividend Yield 10th Percentile 0.2%
China Bottom 25% Dividend Yield 25th Percentile 0.5%
China Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SHSE:600085 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.40 4.00
2020-12-31 0.35 5.00
2020-04-01
2019-12-31 0.41 2.00
SHSE:600085 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2019-07-22 0.260 0.959
2018-08-01 0.250 0.847
2017-08-09 0.240 0.702
2016-08-03 0.230 0.725
2015-08-03 0.220 0.770
2014-08-06 0.200 0.842
2013-08-05 0.250 1.305
2012-03-26 0.150 0.810
2011-03-22 0.140 0.935
2010-03-24 0.092 0.798

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Beijing Tongrentang's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (2.9x coverage).
X
Income/ dividend checks
We assess Beijing Tongrentang's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Beijing Tongrentang afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Beijing Tongrentang has a total score of 5/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

600085 Management

 What is the CEO of Beijing Tongrentang's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shubing Yan
AGE 44
CEO Bio

Mr. Yan Shubing serves as General Manager at Beijing Tongrentang Co., Ltd.

CEO Compensation
  • Insufficient data for Shubing to compare compensation growth.
  • Insufficient data for Shubing to establish whether their remuneration is reasonable compared to companies of similar size in China.
Management Team

Feng Mei

TITLE
Chief Accountant & Director
COMPENSATION
CN¥574K
AGE
48

Gong Pei Zhu

TITLE
Deputy General Manager
COMPENSATION
CN¥536K
AGE
59

Qing Quan Wang

TITLE
Deputy General Manager
AGE
54

Zetao Jia

TITLE
Director
COMPENSATION
CN¥536K
AGE
42

Shubing Yan

TITLE
General Manager
AGE
44

Tian Wang

TITLE
Deputy General Manager
AGE
50

Zhaohua Zhang

TITLE
Deputy General Manager
AGE
44
Board of Directors

Gao Zhenkun

TITLE
Chairman of the Board of Directors
AGE
55
TENURE
4.8 yrs

Feng Mei

TITLE
Chief Accountant & Director
COMPENSATION
CN¥574K
AGE
48

Zetao Jia

TITLE
Director
COMPENSATION
CN¥536K
AGE
42

Fuguo Mao

TITLE
Chairman of the Supervisory Board
AGE
41

Yuan Liu

TITLE
Independent Director
COMPENSATION
CN¥100K
AGE
72

Ying Wang

TITLE
Independent Director
COMPENSATION
CN¥100K
AGE
65

Hui Wang

TITLE
Independent Director
COMPENSATION
CN¥100K
AGE
65

Yi Zang

TITLE
Director
AGE
42

Baigang Liu

TITLE
Director
AGE
51

Jie Man

TITLE
Director
AGE
44
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CN¥) Value (CN¥)
X
Management checks
We assess Beijing Tongrentang's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Beijing Tongrentang has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

600085 News

Simply Wall St News

600085 Company Info

Description

Beijing Tongrentang Co., Ltd engages in the scientific research, production, sale, and distribution of Chinese medicines in China and internationally. It covers 28 product formulations, such as pills, powders, wines and capsules, oral liquids, and dripping pills with the original powder preparation in the areas of cardiovascular, cerebrovascular, and gynecological diseases, as well as anti-depressive new drugs. The company sells its products under the brand names of Angong Niuhuang Wan, Tongren Dahuo Wan Pills, Tongren Niuhuang Qingxin Pills, Zi Xuesan, National wine, Tongren Wuji Baifeng Pills, Zhuanggu medicinal liquor, Bureau Fang Zhibao, Reconstituted pill, and Yufeng Ningxin Dropping Pills. The company was founded in 1669 and is based in Beijing, China. Beijing Tongrentang Co., Ltd is a subsidiary of China Beijing Tongrentang (Group) Co., Ltd.

Details
Name: Beijing Tongrentang Co., Ltd
600085
Exchange: SHSE
Founded: 1669
CN¥34,081,036,010
1,371,470,262
Website: http://www.tongrentanggf.com
Address: Beijing Tongrentang Co., Ltd
No. 42 Chongwenmenwai Street,
Dongcheng District,
Beijing,
100062,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SHSE 600085 Domestic Shares Shanghai Stock Exchange CN CNY 02. Jun 1999
XSSC 600085 Domestic Shares Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect CN CNY 02. Jun 1999
Number of employees
Current staff
Staff numbers
17,139
Beijing Tongrentang employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/01 15:03
End of day share price update: 2020/04/01 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2019/10/30
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.